115 related articles for article (PubMed ID: 16258987)
1. Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs.
Wilson WI; Peng Y; Augsburger LL
J Pharm Sci; 2005 Dec; 94(12):2764-76. PubMed ID: 16258987
[TBL] [Abstract][Full Text] [Related]
2. Generalization of a prototype intelligent hybrid system for hard gelatin capsule formulation development.
Wilson WI; Peng Y; Augsburger LL
AAPS PharmSciTech; 2005 Oct; 6(3):E449-57. PubMed ID: 16354004
[TBL] [Abstract][Full Text] [Related]
3. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
[TBL] [Abstract][Full Text] [Related]
5. Investigations into the relationship between drug properties, filling, and the release of drugs from hard gelatin capsules using multivariate statistical analysis.
Hogan J; Shue PI; Podczeck F; Newton JM
Pharm Res; 1996 Jun; 13(6):944-9. PubMed ID: 8792437
[TBL] [Abstract][Full Text] [Related]
6. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium lauryl sulfate in dissolution media on dissolution of hard gelatin capsule shells.
Zhao F; Malayev V; Rao V; Hussain M
Pharm Res; 2004 Jan; 21(1):144-8. PubMed ID: 14984269
[TBL] [Abstract][Full Text] [Related]
8. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules.
Guadalupe Sánchez-González E; Yépez-Mulia L; Jesús Hernández-Abad V; Jung Cook H
Pharm Dev Technol; 2015 May; 20(3):306-13. PubMed ID: 24417644
[TBL] [Abstract][Full Text] [Related]
9. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
10. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
Garbacz G; Cadé D; Benameur H; Weitschies W
Eur J Pharm Sci; 2014 Jun; 57():264-72. PubMed ID: 24021609
[TBL] [Abstract][Full Text] [Related]
11. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
[TBL] [Abstract][Full Text] [Related]
12. Potential application of silicified microcrystalline cellulose in direct-fill formulations for automatic capsule-filling machines.
Guo M; Augsburger LL
Pharm Dev Technol; 2003; 8(1):47-59. PubMed ID: 12665197
[TBL] [Abstract][Full Text] [Related]
13. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycine/citric acid on the dissolution stability of hard gelatin capsules.
Adesunloye TA; Stach PE
Drug Dev Ind Pharm; 1998 Jun; 24(6):493-500. PubMed ID: 9876614
[TBL] [Abstract][Full Text] [Related]
15. The influence of additives on the presentation of a drug in hard gelatin capsules.
Newton JM; Razzo FN
J Pharm Pharmacol; 1977 May; 29(5):294-7. PubMed ID: 17694
[TBL] [Abstract][Full Text] [Related]
16. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.
Zakowiecki D; Cal K; Kaminski K; Adrjanowicz K; Swinder L; Kaminska E; Garbacz G
AAPS PharmSciTech; 2015 Aug; 16(4):922-33. PubMed ID: 25588366
[TBL] [Abstract][Full Text] [Related]
17. Applications of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products.
Qureshi SA; Shabnam J
Eur J Pharm Sci; 2003 Jul; 19(4):291-7. PubMed ID: 12885394
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dissolution profiles for sustained release resinates of BCS class I drugs using USP apparatus 2 and 4: a technical note.
Prabhu NB; Marathe AS; Jain S; Singh PP; Sawant K; Rao L; Amin PD
AAPS PharmSciTech; 2008; 9(3):769-73. PubMed ID: 18563575
[No Abstract] [Full Text] [Related]
19. Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
Lu X; Xiao B; Lo L; Bolgar MS; Lloyd DK
J Pharm Biomed Anal; 2011 Aug; 56(1):23-9. PubMed ID: 21620602
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
